2021 / 03

Следующая статья
DOI: 10.47183/mes.2021.030

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ

Оценка гепатопротекторного эффекта антиоксидантов на амиодарон-индуцированную цитотоксичность в клетках гепатомы человека линии HepaRG

К. С. Филимонова, Н. Ю. Роговская, П. П. Бельтюков, В. Н. Бабаков
Информация об авторах

Научно-исследовательский институт гигиены, профпатологии и экологии человека Федерального медико-биологического агентства, Ленинградская область, Россия

Для корреспонденции: Владимир Николаевич Бабаков
ст. Капитолово, к. 93, п. Кузьмоловский, Ленинградская область, 188663; ur.hcepg@vokabab

Статья получена: 20.07.2021 Статья принята к печати: 11.08.2021 Опубликовано online: 23.09.2021
|
  1. Ивашкин В. Т., Барановский А. Ю., Райхельсон К. Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (1): 101–31.
  2. Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016; 10 (4): 517–36.
  3. Mujović N, Dobrev D, Marinković M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res. 2020; 151: 104521.
  4. Hashmi A, Keswani NR, Kim S, et al. Hepatic dysfunction in patients receiving intravenous amiodarone. South Med J. 2016; 109 (2): 83–6.
  5. Waldhauser KM, Török M, Ha H-R, et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther. 2006; 319 (3): 1413–23.
  6. Serviddio G, Bellanti F, Giudetti AM, et al. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic Biol Med. 2011; 51 (12): 2234–42.
  7. Golli-Bennour EE, Bouslimi A, Zouaoui O, et al. Cytotoxicity effects of amiodarone on cultured cells. Exp Toxicol Pathol. 2012; 64 (5): 425–30.
  8. Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepatitis. Toxicol Appl Pharmacol. 2015; 289 (1): 40–7.
  9. Grünig D, Duthaler U, Krähenbüh S. Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells. Front Pharmacol. 2018; 9: 257.
  10. Erez N, Hubel E, Avraham R, et al. Hepatic amiodarone lipotoxicity is ameliorated by genetic and pharmacological inhibition of endoplasmatic reticulum stress. Toxicol Sci. 2017; 159 (2): 402–12.
  11. Durukan AB, Erdem B, Durukan E, et al. May toxicity of amiodarone be prevented by antioxidants? A cell-culture study. J Cardiothorac Surg. 2012; 7 (1): 61.
  12. Galli F, Azzi A, Birringer M, et al. Vitamin E: Emerging aspects and new directions. Free Radic Biol Med. 2017; 102: 16–36.
  13. Chughlay MF, Kramer N, Spearman CW, et al. N‐acetylcysteine for non–paracetamol drug–induced liver injury: a systematic review. Br J Clin Pharmacol. 2016; 81: 1021–9.
  14. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol. 2012; 57 (5): 1097–109.
  15. Aninat C, Piton A, Glaise D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 2006; 34 (1): 75–83.
  16. Yokoyama Y, Sasaki Y, Terasaki N, et al. Comparison of drug metabolism and its related hepatotoxic effects in HepaRG, cryopreserved human hepatocytes, and HepG2 cell cultures. Biol Pharm Bull. 2018; 41 (5): 722–32.
  17. Tomida T, Okamura H, Yokoi T, et al. A modified multiparametric assay using HepaRG cells for predicting the degree of druginduced liver injury risk. J Appl Toxicol. 2017; 37 (3): 382–90.
  18. Wu Y, Geng X, Wang J, et al. The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury. Cell Biol Toxicol. 2016; 32 (1): 37–59.
  19. McGovern B, Garan H, Ruskin JN. Serious adverse effects of amiodarones. Clin Cardiol. 1984; 7 (3): 131–7.
  20. Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012; 44 (1): 34–87.
  21. Anthérieu S, Rogue A, Fromenty B, et al. Induction of vesicular steatosis by amiodarone and tetracycline is associated with upregulation of lipogenic genes in heparg cells. Hepatology. 2011; 53 (6): 1895–905.
  22. Ye H, Nelson LJ, Gómez del Moral M, et al. Dissecting the molecular pathophysiology of drug induced liver injury. World J Gastroenterol. 2018; 24 (13): 1373–85.
  23. Yuan L, Kaplowitz N. Mechanisms of drug induced liver injury. Clin Liver Dis. 2013; 17 (4): 507–18.
  24. Iorga A., Dara L. Cell death in drug-induced liver injury. Adv Pharmacol. 2019; 85: 31–74.
  25. Ali SE, Waddington JC, Park BK, et al. Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury. Chem Res Toxicol. 2020; 33 (1): 61–76.
  26. Bognar Z, Fekete K, Antus C, et al. Desethylamiodarone — A metabolite of amiodarone — Induces apoptosis on T24 human bladder cancer cells via multiple pathways. PLoS One. 2017; 12 (12): e0189470.
  27. Steinberg E, Fluksman A, Zemmour C, et al. Low dose amiodarone reduces tumor growth and angiogenesis. Sci Rep. 2020; 10 (1): 18034.
  28. Abdulkhaleq F, Alhussainy T, Badr M, et al. Antioxidative stress effects of vitamins C, E, and B12, and their combination can protect the liver against acetaminophen-induced hepatotoxicity in rats. Drug Des Devel Ther. 2018; 12: 3525–33.